SOLIGENIX, INC. (SNGX)
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Address
29 EMMONS DRIVE
PRINCETON, NJ 08540
Founded
1987
Number of Employees
15
Website
http://www.soligenix.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)